Ultragenyx Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	560.23	434.25	363.33	351.41	271.03	Upgrade
Revenue Growth (YoY)	29.01%	19.52%	3.39%	29.66%	161.32%	Upgrade
Cost of Revenue	774.59	693.66	734.11	513.16	418.21	Upgrade
Gross Profit	-214.36	-259.41	-370.78	-161.76	-147.18	Upgrade
Selling, General & Admin	321.61	309.8	278.14	219.98	182.93	Upgrade
Operating Expenses	321.61	309.8	278.14	219.98	182.93	Upgrade
Operating Income	-535.97	-569.21	-648.92	-381.74	-330.12	Upgrade
Interest Expense	-63.04	-66	-43.02	-29.42	-33.29	Upgrade
Interest & Investment Income	36.51	26.69	11.07	1.93	7.04	Upgrade
Other Non Operating Income (Expenses)	-3.96	-0.34	-1.57	-1.69	0.61	Upgrade
EBT Excluding Unusual Items	-566.47	-608.86	-682.43	-410.92	-355.76	Upgrade
Gain (Loss) on Sale of Investments	-1.12	0.4	-19.3	-42.06	170.4	Upgrade
Pretax Income	-567.59	-608.46	-701.73	-452.98	-185.36	Upgrade
Income Tax Expense	1.6	-1.83	5.7	1.04	1.21	Upgrade
Net Income	-569.18	-606.64	-707.42	-454.03	-186.57	Upgrade
Net Income to Common	-569.18	-606.64	-707.42	-454.03	-186.57	Upgrade
Shares Outstanding (Basic)	91	74	70	68	61	Upgrade
Shares Outstanding (Diluted)	91	74	70	68	61	Upgrade
Shares Change (YoY)	23.11%	5.19%	3.13%	11.42%	7.54%	Upgrade
EPS (Basic)	-6.29	-8.25	-10.12	-6.70	-3.07	Upgrade
EPS (Diluted)	-6.29	-8.25	-10.12	-6.70	-3.07	Upgrade
Free Cash Flow	-421.68	-519.07	-496.59	-411.79	-176.13	Upgrade
Free Cash Flow Per Share	-4.66	-7.06	-7.10	-6.07	-2.90	Upgrade
Gross Margin	-38.26%	-59.74%	-102.05%	-46.03%	-54.31%	Upgrade
Operating Margin	-95.67%	-131.08%	-178.60%	-108.63%	-121.80%	Upgrade
Profit Margin	-101.60%	-139.70%	-194.70%	-129.20%	-68.84%	Upgrade
Free Cash Flow Margin	-75.27%	-119.53%	-136.68%	-117.18%	-64.98%	Upgrade
EBITDA	-500.43	-543.2	-630.7	-368.5	-317.86	Upgrade
EBITDA Margin	-89.33%	-125.09%	-173.59%	-104.86%	-117.28%	Upgrade
D&A For EBITDA	35.54	26.01	18.22	13.24	12.26	Upgrade
EBIT	-535.97	-569.21	-648.92	-381.74	-330.12	Upgrade
EBIT Margin	-95.67%	-131.08%	-178.60%	-108.63%	-121.80%	Upgrade
Revenue as Reported	560.23	434.25	363.33	351.41	271.03	Upgrade

Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q